Cargando…

Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies

OBJECTIVE: We assessed the efficacy and safety of a weekly pegylated human growth hormone (PEG-rhGH) (Jintrolong) vs daily rhGH for children with growth hormone deficiency (GHD). DESIGN: Phase II and III, multicenter, open-label, randomized controlled trials. METHODS: 108 and 343 children with treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Xiaoping, Hou, Ling, Liang, Li, Dong, Guanping, Shen, Shuixian, Zhao, Zhuhui, Gong, Chun Xiu, Li, Yuchuan, Du, Min-lian, Su, Zhe, Du, Hongwei, Yan, Chaoying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2017
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488390/ https://www.ncbi.nlm.nih.gov/pubmed/28566441 http://dx.doi.org/10.1530/EJE-16-0905

Ejemplares similares

PEGylated Recombinant Human Growth Hormone Jintrolong(®) Exhibits Good Long-Term Safety in Cynomolgus Monkeys and Human Pediatric Growth Hormone Deficiency Patients
por: Wu, Wei, et al.
Publicado: (2022)

The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency
por: Liang, Yan, et al.
Publicado: (2022)

Comparative evaluation of short-term biomarker response to treatment for growth hormone deficiency in Chinese children with growth hormone deficiency born small for or appropriate for gestational age: a randomized phase IV open-label study
por: Lu, Wenli, et al.
Publicado: (2013)

Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children
por: Hou, Ling, et al.
Publicado: (2015)

Use of PEGylated Recombinant Human Growth Hormone in Chinese Children with Growth Hormone Deficiency: A 24-Month Follow-Up Study
por: Qiao, Yu, et al.
Publicado: (2019)

Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial
por: Sun, Chengjun, et al.
Publicado: (2021)

Corrigendum: Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial
por: Sun, Chengjun, et al.
Publicado: (2021)

Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations
por: Christiansen, Jens Sandahl, et al.
Publicado: (2016)

SAT-283 Generation of a Long-Acting Human Growth Hormone Receptor Antagonist by Site-Specific Pegylation
por: Wang, Yue, et al.
Publicado: (2020)

A Randomized Controlled Phase 3 Study on the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Idiopathic Short Stature
por: Yuan, Jinna, et al.
Publicado: (2022)

Long‐acting growth hormone in 2022
por: Steiner, Margaret, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Recombinant Human Growth Hormone in Children Born Small for Gestational Age
por: Wu, Wei, et al.
Publicado: (2023)

MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults
por: Strasburger, Christian J, et al.
Publicado: (2016)

A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency
por: Höybye, Charlotte, et al.
Publicado: (2017)

Effects of different doses of long-acting growth hormone in treating children with growth hormone deficiency
por: Xia, Wei, et al.
Publicado: (2023)

Hormones Act in Concert to Direct Plant Growth
Publicado: (2004)

Long acting growth hormone (LAGH), an update
por: Grillo, Margaret Steiner, et al.
Publicado: (2023)

OR17-4 Transcon Growth Hormone In The Treatment Of Pediatric Growth Hormone Deficiency: Results Of The Phase 3 Height Trial
por: Thornton, Paul, et al.
Publicado: (2019)

Multi-centre phase IV trial to investigate the immunogenicity of a new liquid formulation of recombinant human growth hormone in adults with growth hormone deficiency
por: Johannsson, G., et al.
Publicado: (2018)

Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation
por: Bidlingmaier, Martin, et al.
Publicado: (2022)

Effect of Vitamin D Combined with Recombinant Human Growth Hormone in Children with Growth Hormone Deficiency
por: Wang, Pingping, et al.
Publicado: (2022)

Corrigendum: Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation
por: Bidlingmaier, Martin, et al.
Publicado: (2023)

Effect of switching recombinant human growth hormone: Comparative analysis of phase 3 clinical data
por: Romer, Tomasz, et al.
Publicado: (2011)

OR10-06 Somatrogon Growth Hormone in the Treatment of Pediatric Growth Hormone Deficiency: Results of the Pivotal Pediatric Phase 3 Clinical Trial
por: Deal, Cheri L, et al.
Publicado: (2020)

Recombinant growth hormone therapy in children with Turner Syndrome in Korea: a phase III Randomized Trial
por: Kim, Jinsup, et al.
Publicado: (2021)

Association of change on insulin-like growth factor (IGF)-i and IGF-binding protein 3 with genetic markers after a month of growth hormone (GH) therapy on Chinese children born with GH deficiency
por: Wang, Wei, et al.
Publicado: (2013)

Study on the Reparative Effect of PEGylated Growth Hormone on Ovarian Parameters and Mitochondrial Function of Oocytes From Rats With Premature Ovarian Insufficiency
por: Feng, Penghui, et al.
Publicado: (2021)

An examination of the effects of different doses of recombinant human growth hormone on children with growth hormone deficiency
por: XUE, YING, et al.
Publicado: (2016)

Perspectives on long-acting growth hormone therapy in children and adults
por: Lal, Rayhan A., et al.
Publicado: (2019)

Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs
por: Yuen, Kevin C. J., et al.
Publicado: (2021)

Effect of Weekly Long-Acting Growth Hormone Replacement Therapy Compared to Daily Growth Hormone on Children With Short Stature: A Meta-Analysis
por: Ma, Liyan, et al.
Publicado: (2021)

Gonadotropin-releasing hormone analogue and recombinant human growth hormone treatment for idiopathic central precocious puberty in girls
por: Shi, Yuzhen, et al.
Publicado: (2022)

Inhibitory Role of Growth Hormone in the Induction and Progression Phases of Collagen-Induced Arthritis
por: Villares, Ricardo, et al.
Publicado: (2018)

Growth hormone response to growth hormone-releasing peptide-2 in growth hormone-deficient Little mice
por: Peroni, Cibele N., et al.
Publicado: (2012)

Effect of growth hormone releasing hormone on chondrocytes of osteoarthritis
por: LI, Zhuoran, et al.
Publicado: (2022)

Effects of recombinant human growth hormone administration on cardiovascular risk factors in obese children with relative growth hormone deficiency
por: Liang, Shuang, et al.
Publicado: (2018)

Thyroid Hormone Changes Related to Growth Hormone Therapy in Growth Hormone Deficient Patients
por: Kucharska, Anna Małgorzata, et al.
Publicado: (2021)

Growth Hormone-Releasing Hormone in Diabetes
por: Fridlyand, Leonid E., et al.
Publicado: (2016)

Sex Hormones, Growth Hormone, and the Cornea
por: McKay, Tina B., et al.
Publicado: (2022)

Growth hormone treatment in non-growth hormone-deficient children
por: Loche, Sandro, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qae4pdnm4vmidn75guhjbtr5l3